| Description | Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Aurothiomalate sodium (Miochrysin) is a potent and selective inhibitor of oncogenic PKC-ι signaling. Aurothiomalate sodium is a potent thioredoxin reductase (TrxR) inhibitor. Aurothiomalate sodium exhibits potent anti-tumor activity. |
| Synonyms | 金硫丁二钠, Myocrisin, Myocrisine, Miochrysin, Sodium aurothiomalate, Myochrysine, gold sodium thiomalate |
| molecular weight | 390.07 |
| Molecular formula | C4H3AuNa2O4S |
| CAS | 12244-57-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: 200 mg/mL DMSO: Insoluble |
| References | 1. Nummenmaa E, Hämäläinen M, Moilanen LJ, Moilanen T, Vuolteenaho K, Moilanen E. TRPA1 expression is downregulated by dexamethasone and aurothiomalate in human chondrocytes: TRPA1 as a novel factor and drug target in arthritis. RMD Open. 2017 Sep 4;3(2):e000556. 2. Darabi F, Marzo T, Massai L, Scaletti F, Michelucci E, Messori L. Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin. J Inorg Biochem. 2015 Aug;149:102-7. 3. Tuure L, Hämäläinen M, Moilanen T, Moilanen E. Aurothiomalate inhibits the expression of mPGES-1 in primary human chondrocytes. Scand J Rheumatol. 2015;44(1):74-9. 4. Scharf VF, Farese JP, Siemann DW, Abbott JR, Kiupel M, Salute ME, Milner RJ. Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model. Anticancer Drugs. 2014 Mar;25(3):332-9. |